Publications by authors named "S S Astakhov"

This review explores the intricate relationship between glaucoma and circadian rhythm disturbances. As a principal organ for photic signal reception and transduction, the eye plays a pivotal role in coordinating the body's circadian rhythms through specialized retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs). These cells are critical in transmitting light signals to the suprachiasmatic nucleus (SCN), the central circadian clock that synchronizes physiological processes to the 24-hour light-dark cycle.

View Article and Find Full Text PDF

Unlabelled: The rise in the number of glaucoma drugs complicates the choice that the ophthalmologists have to do.

Purpose: The study compares the effectiveness, safety and usability of the Russian latanoprost drug Trilaktan and the drug Xalatan in monotherapy for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH).

Material And Methods: This is a multicenter observational study of the effectiveness and safety of eye drops Trilaktan (Groteks, Russia) and Xalatan (Pfizer MFG.

View Article and Find Full Text PDF
Article Synopsis
  • * Conducted as a double-masked, randomized phase 3 trial, participants were assigned to receive either SB15 or AFL, with some switching treatments mid-study, allowing for a direct comparison of outcomes.
  • * Results showed that both SB15 and AFL had similar impacts on visual acuity and retinal thickness, and both safety and immunogenicity profiles were comparable, indicating that SB15 could be a viable alternative to AFL in nAMD treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Aflibercept biosimilars like SB15 can enhance treatment options for retinal diseases, potentially increasing patient access to effective therapies.
  • A phase 3 trial was conducted with 449 participants aged 50 and older with neovascular age-related macular degeneration to compare the efficacy and safety of SB15 and the reference drug, Aflibercept (AFL).
  • The results showed that SB15 produced comparable improvements in visual acuity as AFL after 8 weeks, indicating equivalence in efficacy between the two treatments.
View Article and Find Full Text PDF